Extended Data Fig. 3: Association between the variation in quantitative butyrate production potential and the BMI, fat mass percentage and triglycerides levels of participants, or the enterotype classification of the samples, in the non-statin-medicated BMIS cohort (n = 782 participants).
From: Statin therapy is associated with lower prevalence of gut microbiota dysbiosis
Quantitative functional microbiome profiles were constructed by multiplication of relative proportions to an indexing factor proportional to the microbial load of the samples. The module ‘butyrate production II’ describes butyrate production from the butyryl-CoA–acetate CoA-transferase pathway—the most common among colon bacteria. a–d, The abundance of the butyrate production II module was negatively correlated with BMI (n = 771 biologically independent samples, Spearman’s ρ = −0.27, Padj = 3.1 × 10−13) (a), fat mass percentage (n = 771 biologically independent samples, Spearman’s ρ = −0.21, Padj = 6.0 × 10−8) (b) and tryglyceride levels (n = 771 biologically independent samples, Spearman’s ρ = −0.20, Padj = 6.4 × 10−8) (c), and significantly decreased in the Bact2 enterotype compared with the others (Bact2 < Prev < Bact1 = Rum; n = 771 biologically independent samples, Kruskal–Wallis Padj = 4.71 × 10−35; different letters denote enterotypes with a significant pairwise difference (post hoc Dunn tests provided in Supplementary Table 10) (d). The body of the box plot represents the first and third quartiles of the distribution, the line represents the median, and the whiskers extend from the quartiles to the last data point within 1.5× IQR, with outliers beyond. In a–d, adjustment for multiple testing (Padj) was performed using the Benjamini–Hochberg method.
